Sign in

Private company

Flexion Therapeutics

American biotechnology company

Flexion Therapeutics, Inc. is an American biopharmaceutical company based in Burlington, Massachusetts that is focused on the discovery, development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the most common form of arthritis. Flexion was founded around 2007 by two former Eli Lilly and Company executives, Michael Clayman and Neil Bodick, and it went public in 2014.3 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

Jan 1, 2007Founded1
  • Industrybiotechnology1
  • HeadquartersWoburn1
  • Websitewww.flexiontherapeutics.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address10 Mall Road, Suite 301, Burlington, Ma 018035
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • LEI549300X8HYW1HZKCDG904
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 44521264

See how the biggest companies compare on our leaderboards

Flexion Therapeutics, Inc. is an American biopharmaceutical company based in Burlington, Massachusetts that is focused on the discovery, development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the most common form of arthritis.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-108.7%Operating margin6
-132.9%Net margin6
17.3%Revenue growth, 20206
-$80.6MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Cost of revenue10¢$19.2M
  • Research and development27¢$54.3M
  • Selling, general and admin53¢$105.0M
  • Interest10¢$20.0M
  • Income tax0¢$495.0K

Out of $85.6M in revenue.6 The company lost money this year.

Financial statements

Revenue76$85.6M in 2020+23999% since 2017
0$25.0M$50.0M$75.0M$100.0M2017: $355.0K$355.0K20172018: $22.5M$22.5M2018+6245%2019: $73.0M$73.0M2019+224%2020: $85.6M$85.6M2020+17%
Operating income891076-$93.0M in 2020+245% since 2014
-$200.0M-$150.0M-$100.0M-$50.0M02014: -$27.0M-$27.0M20142015: -$46.1M-$46.1M2015+71%2016: -$69.8M-$69.8M2016+51%2017: -$129.7M-$129.7M2017+86%2018: -$159.2M-$159.2M2018+23%2019: -$136.3M-$136.3M2019−14%2020: -$93.0M-$93.0M2020−32%
Net income891076-$113.7M in 2020+316% since 2014
-$200.0M-$150.0M-$100.0M-$50.0M02014: -$27.3M-$27.3M20142015: -$46.3M-$46.3M2015+70%2016: -$71.9M-$71.9M2016+55%2017: -$137.5M-$137.5M2017+91%2018: -$169.7M-$169.7M2018+23%2019: -$149.8M-$149.8M2019−12%2020: -$113.7M-$113.7M2020−24%
Fiscal year2014201520162017201820192020
Revenue$355.0K7$22.5M6$73.0M6$85.6M6
Cost of revenue$4.0K7$7.3M6$10.0M6$19.2M6
Research and development$17.9M8$32.7M9$41.3M10$51.2M7$53.1M6$69.6M6$54.3M6
Selling, general and admin$13.4M9$28.5M10$78.8M7$121.3M6$129.7M6$105.0M6
Operating income-$27.0M8-$46.1M9-$69.8M10-$129.7M7-$159.2M6-$136.3M6-$93.0M6
Interest$401.4K8$571.0K9$1.7M10$11.3M7$15.7M6$17.1M6$20.0M6
Income tax$011$09$010$07$06$06$495.0K6
Net income-$27.3M8-$46.3M9-$71.9M10-$137.5M7-$169.7M6-$149.8M6-$113.7M6

Compare Flexion Therapeutics with another company

Corporate structure

Flexion Therapeutics sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Flexion Therapeutics

  • Flexion Therapeutics Burlington, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Flexion Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$29.7M6 Dec 31, 2020$21.6M6 Dec 31, 2019+37.2%
Accumulated depreciation$10.1M6 Dec 31, 2020$8.0M6 Dec 31, 2019+27.4%
Property and equipment, net$19.5M6 Dec 31, 2020$13.7M6 Dec 31, 2019+43.0%
Operating-lease assets (leased space)$6.6M6 Dec 31, 2020$8.2M6 Dec 31, 2019−20.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$107.7M6 Dec 31, 2020$82.3M6 Dec 31, 2019+30.9%
Marketable securities, current$67.6M6 Dec 31, 2020$54.4M6 Dec 31, 2019+24.2%
Marketable securities, non-current$06 Dec 31, 2020$06 Dec 31, 2019
Debt securities available for sale$67.6M6 Dec 31, 2020$54.4M6 Dec 31, 2019+24.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$15.4M6 Dec 31, 2020$16.5M6 Dec 31, 2019−6.9%
Raw materials$4.3M6 Dec 31, 2020$2.8M6 Dec 31, 2019+50.6%
Work in process$4.7M6 Dec 31, 2020$7.6M6 Dec 31, 2019−38.4%
Finished goods$6.4M6 Dec 31, 2020$6.1M6 Dec 31, 2019+5.5%

Leadership

Who has led Flexion Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael D. Clayman2014–2021

President

  1. Michael D. Clayman2014–2021

Chief financial officer

  1. Frederick W. Driscoll2014–2021
  2. David Arkowitz2018–2021
2010201520202025
Board members and other officers (30)

Timeline

  1. Nov 19, 20218-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale39
  2. Oct 12, 20218-K Entered a material agreement; Results of operations; Other events40
  3. Feb 11, 2014New chief executive Michael D. Clayman becomes CEO12
  4. Jan 1, 2007Founded Founded1

Calendar

When it reported results

  1. Oct 12, 2021Reported quarterly or annual results40

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

43 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 19 insider forms, 2 large holders, 19 other. The latest 20:

  1. Nov 29, 202115-12B EDGAR
  2. Nov 24, 2021EFFECT EDGAR
  3. Nov 24, 2021SC 13G SC 13G/A EDGAR
  4. Nov 23, 20214 EDGAR
  5. Nov 23, 20213 EDGAR
  6. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  7. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  8. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  9. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  10. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  11. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  12. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  13. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  14. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  15. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  16. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  17. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  18. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  19. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  20. Nov 19, 20214 FORM 4 SUBMISSION EDGAR

The 43 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Flexion Therapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARFlexion Therapeutics Inc2
  • CIK0001419600
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address10 Mall Road, Suite 301, Burlington, MA 018032
  • Phone(781) 305-77772
  • Shares outstanding50,321,366 as of Nov 1, 202143
  • Public float$587.6M as of Jun 30, 20206
  • On EDGAR sinceNov 21, 20072
  • Filings635 in all: 4 (280), 8-K (93), SC 13G/A (44), 3 (34), 10-Q (24), SC 13G (21), 4/A (12), 424B5 (9)2
    All 44 form types

    S-8 (9), S-8 POS (9), 10-K (8), CT ORDER (8), CORRESP (7), DEF 14A (7), DEFA14A (7), EFFECT (6), SC 13D/A (5), SC 14D9/A (5), REGDEX (4), SC TO-T/A (4), UPLOAD (4), 3/A (3), S-1/A (3), S-3 (3), 424B4 (2), D (2), DRS/A (2), POS AM (2), S-1 (2), SC 13D (2), 10-Q/A (1), 15-12B (1), 25-NSE (1), 8-A12B (1), 8-K/A (1), ARS (1), CERTNAS (1), DRS (1), FWP (1), S-1MEF (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 10, 2021
    Quarterly report (10-Q) Nov 12, 2021
    Proxy statement (DEF 14A) Apr 29, 2021
    Latest 8-K (8-K) Nov 19, 2021

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43